Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy The VANISH Randomized Clinical Trial

Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy The VANISH Randomized Clinical Trial'. Together they form a unique fingerprint.

INIS

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science